Search Results - "Cruellas Lapeña, M."

Changing trends in HIV and cancer by Fernández Ruiz, A., Lastra del Prado, R., Iranzo Gomez, P., Rodrigo, A., Callejo Perez, A., Quilez Bielsa, E., Cruellas Lapeña, M., Crusells Canales, M.J., Yubero Esteban, A., Galan Cerrato, N., Lambea Sorrosal, J.J., Murillo Jaso, L., Andres Conejero, R., Escudero Emperador, P., Pujol Obis, E., Saenz Cusi, A., Isla Casado, D.

Get full text

473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors by Cano, K.S. Vega, Javierre, G. Villacampa, Baselga, P. Mascaró, Mirallas, O., Adelantado, E. Zamora, Gomez, L. Sanz, Ortiz, C., Lapena, M. Cruellas, Arumi de Dios, M., Puy, M. Borrell, Filippi-Arriaga, F., Joval, L., Yaringaño, J.G., Martínez-Albaladejo, P., Buch, P.B., Esteban, P., Ruiz-Ortega, L., Manich, C. Saura, Riveiro-Barciela, M., Ezquerra, M. Bellet

Get full text

165P EPclin, OncotypeDx and Prosigna in lobular breast cancer (ILC): Is there an association with Ki67? by Leao, I.I.L., Zamora, E., Cayuela, R., Villacampa Javierre, G., Gomez Pardo, P., Arumi de Dios, M.A., Pimentel, I., Escriva de Romani, S., Ortiz Velez, C., Cruellas Lapena, M., Sanz, L., Borrell Puy, M., De La Torre, J., Espinosa-bravo, M., Gorria, T., Oliveira, M., Saura Manich, C., Peg, V., Vidal Losada, M.J., Bellet Ezquerra, M.

Get full text

87P EPClin vs OncotypeDx in invasive lobular cancer (ILC) by Leao, I., Zamora, E., Gomez Pardo, P., Arumi de Dios, M.A., Pimentel, I., Escriva de Romani, S., Ortiz Velez, C., Cruellas Lapena, M., Sanz, L., Borrell, M., Vega Cano, K.S., Gómez-Puerto, D., De La Torre, J., Espinosa-Bravo, M., Oliveira, M., Fasani, R., Nuciforo, P.G., Saura, C., Peg, V., Bellet, M.

Get full text

139P Breast cancer risk estimation (CanRisk tool) and perception in unaffected women with family history of breast cancer by Ramon y Cajal, T., Lopez-Fernandez, À., Pardo, M., Darder, E., Perez, E., Costal, A., Teule, A., Perez, A., Torres, M., Alfonso, R., Vallmajó, A., Tuset Der-Abrain, N., Cruellas Lapena, M., Espinosa-Bravo, M., Diez, O., Lázaro, C., Feliubadaló, L., Llort Pursals, G., Brunet Vidal, J.M., Balmaña, J.

Get full text

1424P - Thermal liquid biopsy as a valuable tool in lung cancer screening programs by Rodrigo, A., Vega, S., Ojeda Cabrera, J., Sanchez-Gracia, O., Callejo, A., Fernandez, A., Iranzo, P., Cruellas Lapena, M., Quilez Bielsa, E., Velazquez-Campoy, A., Abian, O., Isla, D.

“…Implementing screening programs for risk populations can reduce lung cancer mortality by detecting the disease at early stages, when surgical intervention or…”
Get full text

1424PThermal liquid biopsy as a valuable tool in lung cancer screening programs by Rodrigo, A, Vega, S, Ojeda Cabrera, J, Sanchez-Gracia, O, Callejo, A, Fernandez, A, Iranzo, P, Cruellas Lapena, M, Quilez Bielsa, E, Velazquez-Campoy, A, Abian, O, Isla, D

“…Abstract Background Implementing screening programs for risk populations can reduce lung cancer mortality by detecting the disease at early stages, when…”
Get full text

Thermal liquid biopsy as a valuable tool in lung cancer screening programs by Rodrigo, A., Vega, S., Ojeda Cabrera, J., Sanchez-Gracia, O., Callejo, A., Fernandez, A., Iranzo, P., Cruellas Lapena, M., Quilez Bielsa, E., Velazquez-Campoy, A., Abian, O., Isla, D.

Get full text

166P Clinical use of tumor sequencing for identification of germline pathogenic variants (gPV) in breast cancer (BC): The SEQ project by Lapena, M. Cruellas, Papakonstantinou, A., Castillo, E., Rezqallah Aron, M.A., Torres, M., Cano, K.S. Vega, Matito, J., Gómez, M., Garces, V. Navarro, Manich, C. Saura, Vivancos, A., Oliveira, M., Balmaña, J.

Get full text

27P Impact of chemotherapy (CT) use and stromal tumor-infiltrating lymphocytes (sTILs) in stage I triple-negative breast cancer (TNBC) by Barberi, V., Panet, F., Joval, L., Jaramillo, J.F. Chabla, Adelantado, E. Zamora, Pimentel, I., Puy, M. Borrell, Ezquerra, M. Bellet, Arumi de Dios, M.A., Gomez, L. Sanz, Calzado, E. Monescillo, Ortiz, C., Rezqallah Aron, M.A., Escrivá-De-Romaní, S., Lapena, M. Cruellas, Jimenez, J., Espinosa-Bravo, M., Cámara, V. Peg, Manich, C. Saura, Oliveira, M.

Get full text

164P Incorporation of the polygenic risk score (PRS) in breast cancer (BC) risk estimation among carriers of a moderate penetrance pathogenic variant (MPPV) by Aron, M.A. Rezqallah, Duran-Lozano, L., López-Fernández, A., Darder, E., Alfonso, R., Cartró, M., Jiménez-Macedo, A.R., Bareas, A., Lapena, M. Cruellas, Moles-Fernández, A., Torres, M., Vallmajó, A., Pursals, G. Llort, Lloveras, A. Roqué, Llorente, C., Espinosa-Bravo, M., Tuset, N., Ramon y Cajal, T., Vidal, J.M. Brunet, Gelpi, J. Balmaña

Get full text

115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts) by Gomez, L. Sanz, Zamora, E., Joval, L., Velez, C. Ortiz, Puy, M. Borrell, Arumi de Dios, M.A., Puerto, D.A. Gomez, Garces, V. Navarro, Rezqallah Aron, M.A., Cano, K.S. Vega, Escrivá-De-Romaní, S., Mirallas, O., Pimentel, I., Lapena, M. Cruellas, Villacampa, G., Oliveira, M., Manich, C. Saura, Pardo, P. Gomez, Cámara, V. Peg, Bellet-Ezquerra, M.

Get full text

250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi) by Cano, K.S. Vega, Mascaro, P., Mirallas, O., Filippi-Arriaga, F., Joval, L., Zamora, E., Gomez, L. Sanz, Velez, C. Ortiz, Lapena, M. Cruellas, Arumi de Dios, M.A., Puy, M. Borrell, Esteban, P., Ruiz-Ortega, L., Buch, P.B., Yaringaño, J., Lores, G. Molina, Gomez-Puerto, D., Manich, C. Saura, Riveiro-Barciela, M., Bellet-Ezquerra, M.

Get full text